Estimated read time: 4-5 minutes
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
[STK] NYSE:DVA
[IN] HEA MTC
[SU] TDS
-- WITH PHOTO -- TO HEALTH, MEDICAL, AND NATIONAL EDITORS:
DaVita Clinical Research to Present Results on Safety of Biosimilars,
Treating Depression, Burden of Diabetic Foot Ulcers
LAS VEGAS, April 21, 2014 /PRNewswire-USNewswire/ -- DaVita Clinical
Research (DCR), a specialty contract research organization with
services spanning the full spectrum of drug and device development,
today announced that company representatives will present four
abstracts at National Kidney Foundation's (NKF) 2014 Spring Clinical
Meeting, which takes place April 22-26, 2014 in Las Vegas.
The NKF Spring Clinical Meeting is a platform for the nation's leading
kidney care providers to learn about new developments related to all
aspects of nephrology and is expected to attract nearly 3,000 health
care professionals in 2014.
Representatives from DaVita Kidney Care, a division of DaVita
HealthCare Partners Inc., and DCR will present results from both
DaVita's innovative clinical quality initiatives and clinical research
originating from DCR and its research partners.
"Our goal at DaVita is to move up the clinical pyramid and improve
mortality, morbidity and patient quality of life. Innovating through
clinical quality initiatives is one important way we do that," said
Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of
clinical innovation and public policy at DaVita. "Translational
research and meaningful quality initiatives, as are included among
these abstracts, are essential for improving health care. These
findings further solidify DaVita's commitment to investing in improved
patient outcomes."
DaVita will share the results from the following clinical quality
initiatives during the poster session on Wednesday, April 23, from
6:00 to 7:30 p.m.:
-- "Treating depression in the dialysis setting: validating Symptom
Targeted Intervention," presented by Shaun Boyd, L.S.W., poster 155
-- "Root Causes of Lack of Adherence to Mineral Bone Disease (MBD)
Medication in ESRD Patients," presented by Maureen McKinley, L.S.W.,
poster 408
In addition, the findings from the following health outcomes research
studies will be presented during the poster session scheduled for
April 23, from 6:00 p.m. to 7:30 p.m.:
-- "Economic Impact of Ferric Citrate (FC) versus Standard of Care for
Hemodialysis Patients," presented by Steven M. Brunelli, M.D.,
M.S.C.E., poster 156
-- "Disease Burden of Diabetic Foot Ulcers in End-Stage Renal
Disease," presented by Scott Sibbel, Ph.D., M.P.H., poster 221
DCR seeks to advance the future of medicine, the practice of medicine
and to innovate through personalized medicine. DCR and DaVita share a
dedication to improving the health and quality of life for kidney care
patients.
DaVita, DaVita Clinical Research and DCR are trademarks or registered
trademarks of DaVita Healthcare Partners Inc. All other trademarks are
the property of their respective owners.
About DaVita Kidney Care DaVita Kidney Care is a division of DaVita
HealthCare Partners Inc., a Fortune 500@ company that, through its
operating divisions, provides a variety of health care services to
patient populations throughout the United States and abroad. A leading
provider of dialysis services in the United States, DaVita Kidney Care
treats patients with chronic kidney failure and end stage renal
disease. DaVita Kidney Care strives to improve patients' quality of
life by innovating clinical care, and by offering integrated treatment
plans, personalized care teams and convenient health-management
services. As of Dec. 31, 2013, DaVita Kidney Care operated or provided
administrative services at 2,074 outpatient dialysis centers located
in the United States serving approximately 163,000 patients. The
company also operated 73 outpatient dialysis centers located in ten
countries outside the United States. DaVita Kidney Care supports
numerous programs dedicated to creating positive, sustainable change
in communities around the world. The company's leadership development
initiatives and social responsibility efforts have been recognized by
Fortune, Modern Healthcare, Newsweek and WorldBlu. For more
information, please visit DaVita.com.
About DaVita Clinical Research DaVita Clinical Research (DCR), a
wholly owned subsidiary of DaVita HealthCare Partners Inc., uses its
extensive, applied database and real-world healthcare experience to
assist pharmaceutical and medical device companies in the design,
recruitment, and completion of clinical trials including retrospective
and prospective pragmatic trials. DCR's scientific and clinical
expertise spans the lifecycle of product development with more than
150 client companies. DCR's Biorepository, Early Clinical
Research unit (Phase I-IIa) and Late Phase Clinical Research (Phase
IIb through post-marketing) network of physicians and investigative
sites, data research, Health Economics & Outcomes Research, Central
Laboratory, and Medical Communications are focused on providing
world-class research in both complex/specialty populations and
therapeutic areas, and especially in CKD and ESRD populations. To
learn more about DCR, visit www.davitaclinicalresearch.com.
Logo - http://photos.prnewswire.com/prnh/20140212/DC63568LOGO
Contact Information
Media: Bianca Violante Office: (303) 876-6614 Mobile: (443) 417-6044
Bianca.Violante@DaVita.com
SOURCE DaVita Inc.
-0- 04/21/2014
/Photo: http://photos.prnewswire.com/prnh/20140212/DC63568LOGO
/Web Site: http://www.davita.com
(NYSE:DVA) /
CO: DaVita Inc.
ST: Nevada
IN: HEA MTC
SU: TDS
PRN
-- DC08616 --
0000 04/21/2014 10:07:00 EDT http://www.prnewswire.com
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
